FDA domestic drug manufacturing push belies hollowed-out inspection capacity
A Fox News opinion piece touts incentivizing domestic drug manufacturing as a supply-chain fix, but the administration's concurrent FDA budget cuts and staffing losses undermine the safety of that very supply.
The Fox News piece celebrates relocating drug production to U.S. soil as a win for jobs and security. What it omits is that the same administration has proposed cutting FDA's appropriated budget by 18.6% — from $3.6 billion in FY 2024 to $2.9 billion — and has allowed the agency's investigator vacancy rate to climb from 9% to 16% between November 2021 and June 2024, according to the Government Accountability Office. Those cuts don't just slow reviews; they directly erode the FDA's ability to inspect domestic facilities for quality and safety. A plant in Ohio with fewer inspectors is no safer than one in India.
A stronger approach would pair manufacturing incentives with a robust public-health infrastructure: fully fund FDA inspections, reverse the staffing drain, and close the inspection backlog that GAO flagged as a continuing risk. Real supply-chain security means not just where drugs are made, but how well they are monitored. The administration's own actions — slashing the agency's enforcement capacity even as it touts reshoring — treat safety as an afterthought, not a priority.
The humanitarian alternative
Rather than using domestic manufacturing as a cudgel to justify deregulation, a progressive approach would pair supply chain reshoring with stronger safety standards. Congress should fund the FDA's inspection workforce to ensure all domestic and foreign manufacturing facilities meet the same rigorous safety benchmarks. The Biologics Price Competition and Innovation Act and the Drug Supply Chain Security Act (DSCSA) provide existing legal frameworks for traceability and quality that can be enforced. A true American jobs strategy for pharmaceuticals would include: (1) targeted tax incentives for companies that build new U.S. manufacturing plants meeting higher safety and wage standards, (2) investment in a public option for essential medicine production, and (3) expanded loan programs under the Defense Production Act that condition federal support on adherence to strict quality metrics and worker protections, not just U.S. location.
Falsifiable predictions
What this entry claims will happen, and what data would prove it wrong. The Reckoner revisits these against current reality.
- The FDA will announce within 90 days a significant reduction in foreign drug facility inspections, citing resource reallocation to domestic manufacturing support.
- Drug shortages for essential generics will increase by at least 10% within six months as domestic capacity fails to replace imports and inspection gaps worsen.
Original source — excerpted
news New FDA moves are boosting American jobs and protecting our medicine supply"NEW You can now listen to Fox News articles! For decades, U.S. policymakers have highlighted the vulnerabilities of relying on foreign supply chains for essent..."